Where does Bristol-Myers Squibb Company rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Bristol-Myers Squibb Company ranks #413 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Bristol-Myers Squibb Company hold?

Bristol-Myers Squibb Company holds 1,089 US utility patents granted between 2015 and 2025, spanning 37 technology areas.

What is Bristol-Myers Squibb Company's Innovation Score?

Bristol-Myers Squibb Company has an Innovation Score of 59.3 out of 100 (top 4% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Bristol-Myers Squibb Company focus on?

Bristol-Myers Squibb Company's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 879 patents, ranking #4 of 6,058 assignees active in that subclass. Grants appear in 37 CPC subclasses total.

Is Bristol-Myers Squibb Company's patent grant rate increasing or decreasing?

Bristol-Myers Squibb Company's recent grant velocity is -20% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Bristol-Myers Squibb Company's patents?

Bristol-Myers Squibb Company's patents average 14.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Bristol-Myers Squibb Company patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Bristol-Myers Squibb Company

USPTO PatentsView assignee record - 1,089 granted patents across 37 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Bristol-myers ranks #413 of 49,997 tracked US assignees by granted-patent volume, with 1,089 patents across 37 technology areas.

#413
of 49,997 US assignees by volume: Top 4%
by Innovation Score (59.3/100): 14.8
avg claims per patent: -20%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R413 · US Corporation #413 · 1,089 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-LARGE 1.1K grants
TOP-DECILE #413/49,997
PHOTO-FINISH NTN
CPC-FOCUS A61P · 37 areas
INNOV-PAR 59.3/100
CLAIMS-RICH 14.8 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -20% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: NTN Corporation (±2 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Bristol-myers’s 59.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 24.2 pts (41%) Velocity 4.8 pts (8%) Breadth 21.5 pts (36%) Claim depth 8.9 pts (15%)

Qualcomm Incorporated · highest

85
Beijing Eswin… · near

59
Bristol-Myers Squibb · this assignee

59
Insilico Medicine IP · near

59
Danisco US · near

59
Nidec Motor · near

59
3D Lighting… · lowest

7

What this shows Bristol-myers's Innovation Score is 59.3/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Bristol-myers?

Each dot is one of Bristol-myers’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Bristol-myers’s own 14.8 claims/patent is at or below the 17.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Bristol-myers vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Bristol-myers's grants concentrate

Bristol-Myers Squibb Company is a focused PatentsView assignee: 37 CPC subclasses with 80.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (137 grants) versus a trough of 64 in 2023. By volume, Bristol-myers sits between Boston Scientific Neuromodulation Corporation and CA, Inc..

Bristol-myers's three-year grant acceleration

From 2019–2021 to 2022–2024, Bristol-Myers Squibb Company moved from 343 to 245 grants (0.71x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,103. See the growth leaderboard.

Boston Scientific…

1,098
Thomson Licensing

1,095
Advanced Semicond…

1,092
NTN

1,091
Bristol-myers Squ… ◀

1,089
Yangtze Memory

1,087
The Trustees of C…

1,086
University of Sou…

1,086
CA

1,081

What this shows Bristol-Myers holds 1,089 patents at rank #413, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Bristol-Myers

By rank, the assignees closest to #413 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Bristol-Myers's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Bristol-Myers, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Bristol-Myers ranks #4 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (59 here).

Beijing Eswin Computing Technology Co., Ltd. 59 Insilico Medicine IP Limited 59 Nidec Motor Corporation 59 Danisco US Inc. 59

Similar claim depth

Nearest assignees by average claims per patent (14.8 here).

Airbus Operations Limited 14.8 avg ZTE Corporation 14.8 avg Xi'an Zhongxing NEW Software Co., Ltd. 14.8 avg Owens Corning Intellectual Capital, LLC 14.8 avg

Bristol-myers's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Bristol-Myers Squibb Company patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	91	8.4%
2016	112	10.3%
2017	137	12.6%
2018	97	8.9%
2019	131	12.0%
2020	106	9.7%
2021	106	9.7%
2022	99	9.1%
2023	64	5.9%
2024	82	7.5%
2025partial year	64	5.9%

Which technologies does Bristol-Myers Squibb Company patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 879

C07D - Heterocyclic Compounds 662

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 606

C07K - Peptides 376

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 115

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 81

C07C - Acyclic OR Carbocyclic Compounds 80

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 75

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 67

Y02A - Technologies FOR Adaptation TO Climate Change 60

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 30

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 19

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 19

B01D - Separation 13

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 13

Top 15 of 37 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Bristol-Myers Squibb Company's patent record in context - here's where to go next.

Bristol-Myers Squibb Company's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #413 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Bristol-Myers Squibb Company against Boston Scientific Neuromodulation Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 59.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.